中國醫藥(600056.SH):子公司2個品種擬中標第三批集採
格隆匯8月21日丨中國醫藥(600056.SH)宣佈,2020年8月20日,公司下屬全資子公司天方藥業參加了第三批全國藥品集中採購的投標。根據聯合採購辦公室2020年8月21日發佈的全國藥品集中採購擬中選結果公示顯示,天方藥業已通過仿製藥質量和療效一致性評價的產品鹽酸二甲雙胍緩釋片及非那雄胺片擬中標該次集中採購。
其中,非那雄胺片(1mg)及非那雄胺片(5mg)擬中標數量分別為3.66萬盒及41.35萬盒,價格分別為196元/盒及10.5元/盒;鹽酸二甲雙胍緩釋片(0.5g)擬中標數量為566.53萬盒,價格為4.35元/盒。
該次擬中標的鹽酸二甲雙胍緩釋片及非那雄胺片2019年營業收入合計約為1.50億元,約佔公司2019年度營業收入總額的0.4%。該次擬中標產品首年約定中標數量收入約為3616萬元,約佔公司2019年度營業收入總額的0.1%,預計不會對公司業績產生較大影響。
該次集中採購是國家組織的第三批藥品集中帶量採購,採購週期中,醫療機構將優先使用該次集中採購中選品種,並確保完成約定採購量。若天方藥業後續簽訂採購合同並實施後,將有利於進一步擴大相關產品的銷售,提高市場佔有率,促進該公司有關產品市場的開拓,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.